Home › Neuroblastoma › North Carolina
Neuroblastoma clinical trials in North Carolina
7 studies for Neuroblastoma are looking for participants at sites in North Carolina.
Cities in North Carolina
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- and 4 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Levine Children's Hospital, Charlotte
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Duke University, Durham
RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- and 3 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Levine Children's Hospital, Charlotte
- Duke University, Durham
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingPhase 1
18 Months · All sexes · Updated Mar 27, 2026 · NCT03721068From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.